APLN and cancer: These data showed the synergistic effect of Apelin and VEGF-C and demonstrated that this combination generates a significant therapeutic benefit despite the transient expression of the two transgenes, providing a perspective of LD treatment using nonintegrative RNA delivery vectors for patients who develop LD after cancer treatment.